JP7624431B2 - (r)-n-(5-(5-エチル-1,2,4-オキサジアゾール-3-イル)-2,3-ジヒドロ-1h-インデン-1-イル)-1-メチル-1h-ピラゾール-4-カルボキサミドの多形 - Google Patents

(r)-n-(5-(5-エチル-1,2,4-オキサジアゾール-3-イル)-2,3-ジヒドロ-1h-インデン-1-イル)-1-メチル-1h-ピラゾール-4-カルボキサミドの多形 Download PDF

Info

Publication number
JP7624431B2
JP7624431B2 JP2022502215A JP2022502215A JP7624431B2 JP 7624431 B2 JP7624431 B2 JP 7624431B2 JP 2022502215 A JP2022502215 A JP 2022502215A JP 2022502215 A JP2022502215 A JP 2022502215A JP 7624431 B2 JP7624431 B2 JP 7624431B2
Authority
JP
Japan
Prior art keywords
polymorph
dihydro
inden
ethyl
pyrazole
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022502215A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022540668A (ja
JP2022540668A5 (cg-RX-API-DMAC10.html
Inventor
ノーマ トム,
マシュー ファイファー,
デニス アンデルセン,
チー ガオ,
Original Assignee
サイトキネティックス, インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=71995103&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP7624431(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by サイトキネティックス, インコーポレイテッド filed Critical サイトキネティックス, インコーポレイテッド
Publication of JP2022540668A publication Critical patent/JP2022540668A/ja
Publication of JP2022540668A5 publication Critical patent/JP2022540668A5/ja
Priority to JP2025007662A priority Critical patent/JP7755090B2/ja
Application granted granted Critical
Publication of JP7624431B2 publication Critical patent/JP7624431B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2022502215A 2019-07-17 2020-07-16 (r)-n-(5-(5-エチル-1,2,4-オキサジアゾール-3-イル)-2,3-ジヒドロ-1h-インデン-1-イル)-1-メチル-1h-ピラゾール-4-カルボキサミドの多形 Active JP7624431B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025007662A JP7755090B2 (ja) 2019-07-17 2025-01-20 (r)-n-(5-(5-エチル-1,2,4-オキサジアゾール-3-イル)-2,3-ジヒドロ-1h-インデン-1-イル)-1-メチル-1h-ピラゾール-4-カルボキサミドの多形

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962875350P 2019-07-17 2019-07-17
US62/875,350 2019-07-17
PCT/US2020/042387 WO2021011807A1 (en) 2019-07-17 2020-07-16 Polymorphs of (r)-n-(5-(5-ethyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1h-inden-1-yl)-1-methyl-1h-pyrazole-4-carboxamide

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025007662A Division JP7755090B2 (ja) 2019-07-17 2025-01-20 (r)-n-(5-(5-エチル-1,2,4-オキサジアゾール-3-イル)-2,3-ジヒドロ-1h-インデン-1-イル)-1-メチル-1h-ピラゾール-4-カルボキサミドの多形

Publications (3)

Publication Number Publication Date
JP2022540668A JP2022540668A (ja) 2022-09-16
JP2022540668A5 JP2022540668A5 (cg-RX-API-DMAC10.html) 2023-07-25
JP7624431B2 true JP7624431B2 (ja) 2025-01-30

Family

ID=71995103

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022502215A Active JP7624431B2 (ja) 2019-07-17 2020-07-16 (r)-n-(5-(5-エチル-1,2,4-オキサジアゾール-3-イル)-2,3-ジヒドロ-1h-インデン-1-イル)-1-メチル-1h-ピラゾール-4-カルボキサミドの多形
JP2025007662A Active JP7755090B2 (ja) 2019-07-17 2025-01-20 (r)-n-(5-(5-エチル-1,2,4-オキサジアゾール-3-イル)-2,3-ジヒドロ-1h-インデン-1-イル)-1-メチル-1h-ピラゾール-4-カルボキサミドの多形

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025007662A Active JP7755090B2 (ja) 2019-07-17 2025-01-20 (r)-n-(5-(5-エチル-1,2,4-オキサジアゾール-3-イル)-2,3-ジヒドロ-1h-インデン-1-イル)-1-メチル-1h-ピラゾール-4-カルボキサミドの多形

Country Status (25)

Country Link
US (1) US20220315571A1 (cg-RX-API-DMAC10.html)
EP (2) EP4487911A1 (cg-RX-API-DMAC10.html)
JP (2) JP7624431B2 (cg-RX-API-DMAC10.html)
KR (1) KR20220084008A (cg-RX-API-DMAC10.html)
CN (3) CN118908951A (cg-RX-API-DMAC10.html)
AU (1) AU2020313965B2 (cg-RX-API-DMAC10.html)
BR (1) BR112022000494A2 (cg-RX-API-DMAC10.html)
CA (1) CA3144975A1 (cg-RX-API-DMAC10.html)
CL (1) CL2022000054A1 (cg-RX-API-DMAC10.html)
DK (1) DK3999180T3 (cg-RX-API-DMAC10.html)
ES (1) ES2980885T3 (cg-RX-API-DMAC10.html)
FI (1) FI3999180T3 (cg-RX-API-DMAC10.html)
HR (1) HRP20240713T1 (cg-RX-API-DMAC10.html)
HU (1) HUE066891T2 (cg-RX-API-DMAC10.html)
IL (1) IL289875B1 (cg-RX-API-DMAC10.html)
LT (1) LT3999180T (cg-RX-API-DMAC10.html)
MX (1) MX2022000504A (cg-RX-API-DMAC10.html)
PH (1) PH12022550123A1 (cg-RX-API-DMAC10.html)
PL (1) PL3999180T3 (cg-RX-API-DMAC10.html)
PT (1) PT3999180T (cg-RX-API-DMAC10.html)
RS (1) RS65611B1 (cg-RX-API-DMAC10.html)
SI (1) SI3999180T1 (cg-RX-API-DMAC10.html)
SM (1) SMT202400224T1 (cg-RX-API-DMAC10.html)
TW (1) TWI865562B (cg-RX-API-DMAC10.html)
WO (1) WO2021011807A1 (cg-RX-API-DMAC10.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202006296YA (en) 2018-01-19 2020-08-28 Cytokinetics Inc Dihydrobenzofuran and inden analogs as cardiac sarcomere inhibitors
JP7438148B2 (ja) 2018-06-26 2024-02-26 サイトキネティックス, インコーポレイテッド 心臓サルコメア阻害剤
EP3814343B1 (en) 2018-06-26 2023-01-11 Cytokinetics, Inc. Cardiac sarcomere inhibitors
MA53491A (fr) 2018-08-31 2021-09-15 Cytokinetics Inc Inhibiteurs de sarcomes cardiaques
MX2022000498A (es) 2019-07-17 2022-02-03 Cytokinetics Inc Polimorfos de (r)-n-(5-(5-isopropil-1,2,4-oxadiazol-3-il)-2,3-dihi dro-1h-inden-1-il) -2-metil-2h- tetrazol-5-carboxamida.
KR20240015622A (ko) 2021-03-04 2024-02-05 싸이토키네틱스, 인코포레이티드 심장 근절 억제제
EP4370116B1 (en) 2021-07-16 2025-01-15 Cytokinetics, Inc. Aficamten dosage regimens for treating obstructive hypertrophic cardiomyopathy
JP2024530111A (ja) 2021-08-03 2024-08-16 サイトキネティックス, インコーポレイテッド アフィカムテンを調製するための工程
US20240091203A1 (en) 2022-07-20 2024-03-21 Cytokinetics, Incorporated Methods for treating non-obstructive hypertrophic cardiomyopathy
JP2025525913A (ja) 2022-08-04 2025-08-07 サイトキネティックス, インコーポレイテッド 閉塞性肥大型心筋症を治療するための方法
WO2024134498A1 (en) 2022-12-22 2024-06-27 Assia Chemical Industries Ltd. Solid state forms of aficamten and process for preparation thereof
CN120712262A (zh) * 2023-03-02 2025-09-26 苏州科睿思制药有限公司 Aficamten的共晶及其制备方法和用途
WO2025198687A1 (en) 2024-03-20 2025-09-25 Cytokinetics, Incorporated Methods for treating heart diseases

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019144041A1 (en) 2018-01-19 2019-07-25 Cytokinetics, Inc. Dihydrobenzofuran and inden analogs as cardiac sarcomere inhibitors

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024530111A (ja) * 2021-08-03 2024-08-16 サイトキネティックス, インコーポレイテッド アフィカムテンを調製するための工程

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019144041A1 (en) 2018-01-19 2019-07-25 Cytokinetics, Inc. Dihydrobenzofuran and inden analogs as cardiac sarcomere inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
有機化合物結晶作製ハンドブック-原理とノウハウ-,2008年07月25日,pp. 57-79

Also Published As

Publication number Publication date
IL289875B1 (en) 2026-05-01
CA3144975A1 (en) 2021-01-21
NZ784930A (en) 2025-03-28
IL289875A (en) 2022-03-01
EP4487911A1 (en) 2025-01-08
EP3999180B1 (en) 2024-05-08
JP2022540668A (ja) 2022-09-16
KR20220084008A (ko) 2022-06-21
TWI865562B (zh) 2024-12-11
CN114555590A (zh) 2022-05-27
CN118908951A (zh) 2024-11-08
ES2980885T3 (es) 2024-10-03
JP2025061484A (ja) 2025-04-10
HRP20240713T1 (hr) 2024-09-13
EP3999180A1 (en) 2022-05-25
MX2022000504A (es) 2022-02-10
US20220315571A1 (en) 2022-10-06
CN114555590B (zh) 2024-09-10
BR112022000494A2 (pt) 2022-03-03
PH12022550123A1 (en) 2022-12-19
JP7755090B2 (ja) 2025-10-15
PT3999180T (pt) 2024-06-25
AU2020313965B2 (en) 2026-06-18
AU2020313965A1 (en) 2022-03-03
CL2022000054A1 (es) 2022-10-07
LT3999180T (lt) 2024-08-26
PL3999180T3 (pl) 2024-09-23
WO2021011807A1 (en) 2021-01-21
DK3999180T3 (da) 2024-05-21
RS65611B1 (sr) 2024-07-31
FI3999180T3 (fi) 2024-06-18
SMT202400224T1 (it) 2024-07-09
TW202116763A (zh) 2021-05-01
SI3999180T1 (sl) 2024-07-31
HUE066891T2 (hu) 2024-09-28
CN119119018A (zh) 2024-12-13

Similar Documents

Publication Publication Date Title
JP7755090B2 (ja) (r)-n-(5-(5-エチル-1,2,4-オキサジアゾール-3-イル)-2,3-ジヒドロ-1h-インデン-1-イル)-1-メチル-1h-ピラゾール-4-カルボキサミドの多形
JP7438148B2 (ja) 心臓サルコメア阻害剤
JP7623342B2 (ja) 心臓サルコメア阻害剤の経口用製剤
EP3999181B1 (en) Polymorphs of (r)-n-(5-(5-isopropyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1h-inden-1-yl)-2-methyl-2h-tetrazole-5-carboxamide
CN117083275A (zh) 心脏肌节抑制剂
CN119998292A (zh) 5-(3,4-二氟苄基)-8-((1r,4r)-4-甲基环己基)-6,9-二氧代基-2,5,8-三氮杂螺[3.5]壬烷-2-甲醛的结晶形式
RU2846046C2 (ru) Полиморфы (r)-n-(5-(5-этил-1,2,4,-оксадиазол-3-ил)-2,3-дигидро-1н-инден-1-ил)-1-метил-1н-пиразол-4-карбоксамида
HK40121580A (en) Polymorphs of (r)-n-(5-(5-ethyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1h-inden-1-yl)-1-methyl-1h-pyrazole-4-carboxamide
HK40075684A (en) Polymorphs of (r)-n-(5-(5-ethyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1h-inden-1-yl)-1-methyl-1h-pyrazole-4-carboxamide
HK40076616A (en) Polymorphs of (r)-n-(5-(5-ethyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1h-inden-1-yl)-1-methyl-1h-pyrazole-4-carboxamide
HK40111816A (en) Polymorphs
HK40125944A (en) Crystalline forms of 5-(3,4-difluorobenzyl)-8-((1r,4r)-4-methylcyclohexyl)-6,9-dioxo-2,5,8-triazaspiro[3.5]nonane-2-carbaldehyde
HK40102197A (en) Cardiac sarcomere inhibitors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230714

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230714

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240726

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241028

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20241220

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250120

R150 Certificate of patent or registration of utility model

Ref document number: 7624431

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150